Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825493 | 1.00 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL12420397 | 1.00 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL10533308 | 0.98 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL12680192 | 0.94 | GSR (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL10532179 | 0.94 | GSR (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL18159727 | 0.94 | GSR (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL28257116 | 0.86 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL28257117 | 0.86 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL18159724 | 0.85 | DPP7 (0.40) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL10110827 | 0.85 | DPP7 (0.40) | GSRDPP7DPP8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11541049-B2 | Tetrahydroisoquinoline derivatives, preparation process and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20210292929-A1 | METHODS AND SYSTEMS FOR REDOX-TRIGGERED SURFACE IMMOBILIZATION OF POLYIONIC SPECIES ON A SUBSTRATE | NATIONAL SCIENCE FOUNDATION | 2021-09-23 | — | — | US | disclosed |
| US-20210052576-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-10450423-B2 | Disintegratable porous organometaloxyde material | UNIVERSITE DE STRASBOURG (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-9790417-B1 | High-density water-based drilling fluid suitable for horizontal shale gas wells | CHINA UNIVERSITY OF PETROLEUM (BEIJING) (CN) | 2017-10-17 | — | — | US | disclosed |
| US-9783725-B1 | Drilling fluid additive composition and water-based drilling fluid suitable for horizontal shale gas wells | CHINA UNIVERSITY OF PETROLEUM (BEIJING) (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450423-B2 | Disintegratable porous organometaloxyde material | MCM4, SI, ESD | GSR 1345/4885GNAI3 4254/4885GNAO1 4345/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | GSR 3801/4885GNAI3 173/4885GNAO1 506/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | GSR 2550/4885GNAI3 108/4885GNAO1 743/4885 |
| US-11541049-B2 | Tetrahydroisoquinoline derivatives, preparation process and use thereof | CYP3A4, CYP3A43, CYP11B2 | GSR 3091/4885GNAI3 1425/4885GNAO1 875/4885 |
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | GSR 439/4885GNAI3 3556/4885GNAO1 3280/4885 |
| US-20210052576-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | CYP3A4, CYP3A43, CYP11B2 | GSR 3091/4885GNAI3 1425/4885GNAO1 875/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | GSR 3801/4885GNAI3 173/4885GNAO1 506/4885 |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | GSR 1010/4885GNAI3 2087/4885GNAO1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.